Schieber A, Frank R W, Ghisla S
University of Konstanz, Faculty of Biology, Federal Republic of Germany.
Eur J Biochem. 1992 Jun 1;206(2):491-502. doi: 10.1111/j.1432-1033.1992.tb16952.x.
Prostaglandin 9-ketoreductase (PG-9-KR) was purified from pig kidney to homogeneity, as judged by SDS/PAGE using an improved procedure. The enzyme is pro-S stereoselective with regard to hydrogen transfer from NADPH with prostaglandin E2 as substrate and reduces its 9-keto group with approximately 90% stereoselectivity to form prostaglandin F2 alpha. Approximately 8% of the prostaglandin F formed has the beta-configuration. In addition to catalyzing the interconversion of prostaglandin E2 to F2 alpha, PG-9-KR also oxidizes prostaglandin E2, F2 alpha and D2 to their corresponding, biologically inactive, 15-keto metabolites. Incubation of PG-9-KR with prostaglandin F2 alpha and NAD+ leads to the preferential formation of 15-keto prostaglandin F2 alpha rather than prostaglandin E2. This suggests that the prostaglandin E2/prostaglandin F2 alpha ratio is not determined by the NADP+/NADPH redox couple. The enzyme also reduces various other carbonyl compounds (e.g. 9,10-phenanthrenequinone) with high efficiency. The catalytic properties measured for PG-9-KR suggest that its in vivo function is unlikely to be to catalyze formation of prostaglandin F2 alpha. The monomeric enzyme has a molecular mass of 32 kDa and exists as four isoforms, as judged by isoelectric focusing. PG-9-KR contains 1.9 mol Zn2+/mol enzyme and no other cofactors. Human kidney PG-9-KR was also purified to homogeneity. The human enzyme has a molecular mass of 34 kDa and also exists as four isoforms. Polyclonal antibodies raised against pig kidney PG-9-KR cross-react with human kidney PG-9-KR and also with human brain carbonyl reductase, as demonstrated by Western blot analysis. Sequence data of tryptic peptides from pig kidney PG-9-KR show greater than 90% identity with human placenta carbonyl reductase. From comparison of several properties (catalytical, structural and immunological properties), it is concluded that PG-9-KR and carbonyl reductase are identical enzymes.
通过改进的方法,利用SDS/PAGE判断,从猪肾中纯化得到了均一的前列腺素9-酮还原酶(PG-9-KR)。该酶以前列腺素E2为底物时,在从NADPH转移氢方面具有前-S立体选择性,以大约90%的立体选择性还原其9-酮基团,形成前列腺素F2α。所形成的前列腺素F中约8%具有β构型。除了催化前列腺素E2向F2α的相互转化外,PG-9-KR还将前列腺素E2、F2α和D2氧化为其相应的、无生物活性的15-酮代谢产物。PG-9-KR与前列腺素F2α和NAD+一起孵育时,优先形成15-酮前列腺素F2α而不是前列腺素E2。这表明前列腺素E2/前列腺素F2α的比例不是由NADP+/NADPH氧化还原对决定的。该酶还能高效还原各种其他羰基化合物(如9,10-菲醌)。对PG-9-KR所测定的催化特性表明,其在体内的功能不太可能是催化前列腺素F2α的形成。通过等电聚焦判断,该单体酶的分子量为32 kDa,以四种同工型存在。PG-9-KR每摩尔酶含有1.9摩尔Zn2+,不含其他辅因子。人肾PG-9-KR也被纯化至均一。人酶的分子量为34 kDa,也以四种同工型存在。如蛋白质免疫印迹分析所示,针对猪肾PG-9-KR产生的多克隆抗体与人肾PG-9-KR以及人脑羰基还原酶发生交叉反应。来自猪肾PG-9-KR的胰蛋白酶肽段的序列数据与人胎盘羰基还原酶的序列同一性大于90%。从几种特性(催化、结构和免疫特性)的比较得出结论,PG-9-KR和羰基还原酶是相同的酶。